Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hepatitis B-Pipeline Review, H1 2015

Hepatitis B-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hepatitis B-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hepatitis B-Pipeline Review, H1 2015', provides an overview of the Hepatitis B's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatitis B

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hepatitis B and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hepatitis B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hepatitis B pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hepatitis B

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 6

Hepatitis B Overview 7

Therapeutics Development 8

Hepatitis B-Therapeutics under Development by Companies 10

Hepatitis B-Therapeutics under Investigation by Universities/Institutes 18

Hepatitis B-Pipeline Products Glance 20

Hepatitis B-Products under Development by Companies 24

Hepatitis B-Products under Investigation by Universities/Institutes 32

Hepatitis B-Companies Involved in Therapeutics Development 33

Hepatitis B-Therapeutics Assessment 104

Drug Profiles 115

Hepatitis B-Recent Pipeline Updates 281

Hepatitis B-Dormant Projects 310

Hepatitis B-Discontinued Products 319

Hepatitis B-Product Development Milestones 320

Appendix 327

List of Tables

Number of Products under Development for Hepatitis B, H1 2015 23

Number of Products under Development for Hepatitis B-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 26

Number of Products under Development by Companies, H1 2015 (Contd..1) 27

Number of Products under Development by Companies, H1 2015 (Contd..2) 28

Number of Products under Development by Companies, H1 2015 (Contd..3) 29

Number of Products under Development by Companies, H1 2015 (Contd..4) 30

Number of Products under Development by Companies, H1 2015 (Contd..5) 31

Number of Products under Development by Companies, H1 2015 (Contd..6) 32

Number of Products under Investigation by Universities/Institutes, H1 2015 34

Comparative Analysis by Late Stage Development, H1 2015 35

Comparative Analysis by Clinical Stage Development, H1 2015 36

Comparative Analysis by Early Stage Development, H1 2015 37

Comparative Analysis by Unknown Stage Development, H1 2015 38

Products under Development by Companies, H1 2015 39

Products under Development by Companies, H1 2015 (Contd..1) 40

Products under Development by Companies, H1 2015 (Contd..2) 41

Products under Development by Companies, H1 2015 (Contd..3) 42

Products under Development by Companies, H1 2015 (Contd..4) 43

Products under Development by Companies, H1 2015 (Contd..5) 44

Products under Development by Companies, H1 2015 (Contd..6) 45

Products under Development by Companies, H1 2015 (Contd..7) 46

Products under Investigation by Universities/Institutes, H1 2015 47

Hepatitis B-Pipeline by Abivax S.A., H1 2015 48

Hepatitis B-Pipeline by AiCuris GmbH & Co. KG, H1 2015 49

Hepatitis B-Pipeline by Akshaya Bio Inc., H1 2015 50

Hepatitis B-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 51

Hepatitis B-Pipeline by AlphaMab Co., Ltd, H1 2015 52

Hepatitis B-Pipeline by AltraVax Inc., H1 2015 53

Hepatitis B-Pipeline by Amarna Therapeutics B.V., H1 2015 54

Hepatitis B-Pipeline by Arrowhead Research Corporation, H1 2015 55

Hepatitis B-Pipeline by Assembly Biosciences, Inc., H1 2015 56

Hepatitis B-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 57

Hepatitis B-Pipeline by Benitec Biopharma Limited, H1 2015 58

Hepatitis B-Pipeline by Big DNA Ltd., H1 2015 59

Hepatitis B-Pipeline by BioDiem Ltd, H1 2015 60

Hepatitis B-Pipeline by Biogenomics Limited, H1 2015 61

Hepatitis B-Pipeline by Biological E. Limited, H1 2015 62

Hepatitis B-Pipeline by BioStar Pharmaceuticals, Inc., H1 2015 63

Hepatitis B-Pipeline by Bolder Biotechnology, Inc., H1 2015 64

Hepatitis B-Pipeline by Bukwang Pharm.Co., Ltd., H1 2015 65

Hepatitis B-Pipeline by Celltrion, Inc., H1 2015 66

Hepatitis B-Pipeline by Chimerix, Inc., H1 2015 67

Hepatitis B-Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015 68

Hepatitis B-Pipeline by ChronTech Pharma AB, H1 2015 69

Hepatitis B-Pipeline by Cytos Biotechnology AG, H1 2015 70

Hepatitis B-Pipeline by Dynavax Technologies Corporation, H1 2015 71

Hepatitis B-Pipeline by Enyo Pharma S.A.S., H1 2015 72

Hepatitis B-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 73

Hepatitis B-Pipeline by GeneCure LLC, H1 2015 74

Hepatitis B-Pipeline by Genexine, Inc., H1 2015 75

Hepatitis B-Pipeline by Gilead Sciences, Inc., H1 2015 76

Hepatitis B-Pipeline by GlaxoSmithKline Plc, H1 2015 77

Hepatitis B-Pipeline by Green Cross Corporation, H1 2015 78

Hepatitis B-Pipeline by HEC Pharm Co., Ltd., H1 2015 79

Hepatitis B-Pipeline by Humabs BioMed SA, H1 2015 80

Hepatitis B-Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 81

Hepatitis B-Pipeline by Immunotope, Inc., H1 2015 82

Hepatitis B-Pipeline by Immunovaccine, Inc., H1 2015 83

Hepatitis B-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 84

Hepatitis B-Pipeline by Indian Immunologicals Limited, H1 2015 85

Hepatitis B-Pipeline by iQur Limited, H1 2015 86

Hepatitis B-Pipeline by ISA Pharmaceuticals B.V., H1 2015 87

Hepatitis B-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 88

Hepatitis B-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 89

Hepatitis B-Pipeline by Johnson & Johnson, H1 2015 90

Hepatitis B-Pipeline by Leukocare AG, H1 2015 91

Hepatitis B-Pipeline by LG Life Sciences, Ltd., H1 2015 92

Hepatitis B-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 93

Hepatitis B-Pipeline by Mologen AG, H1 2015 94

Hepatitis B-Pipeline by Mucosis B.V., H1 2015 95

Hepatitis B-Pipeline by MultiCell Technologies, Inc., H1 2015 96

Hepatitis B-Pipeline by Novira Therapeutics, Inc., H1 2015 97

Hepatitis B-Pipeline by Panacea Biotec Limited, H1 2015 98

Hepatitis B-Pipeline by Pfenex Inc., H1 2015 99

Hepatitis B-Pipeline by PharmaEssentia Corporation, H1 2015 100

Hepatitis B-Pipeline by Redx Pharma Plc, H1 2015 101

Hepatitis B-Pipeline by REPLICor Inc., H1 2015 102

Hepatitis B-Pipeline by Romark Laboratories, L.C., H1 2015 103

Hepatitis B-Pipeline by Sanofi Pasteur SA, H1 2015 104

Hepatitis B-Pipeline by SEEK Group, H1 2015 105

Hepatitis B-Pipeline by Sinovac Biotech Ltd., H1 2015 106

Hepatitis B-Pipeline by SK Chemicals Co., Ltd., H1 2015 107

Hepatitis B-Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2015 108

Hepatitis B-Pipeline by TCM Biotech International Corp, H1 2015 109

Hepatitis B-Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 110

Hepatitis B-Pipeline by TetraLogic Pharmaceuticals, H1 2015 111

Hepatitis B-Pipeline by Theravectys S.A., H1 2015 112

Hepatitis B-Pipeline by Transgene SA, H1 2015 113

Hepatitis B-Pipeline by Vaxine Pty Ltd, H1 2015 114

Hepatitis B-Pipeline by Viriom Ltd., H1 2015 115

Hepatitis B-Pipeline by VLP Biotech, Inc., H1 2015 116

Hepatitis B-Pipeline by WaterStone Pharmaceuticals, Inc., H1 2015 117

Hepatitis B-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 118

Assessment by Monotherapy Products, H1 2015 119

Assessment by Combination Products, H1 2015 120

Number of Products by Stage and Target, H1 2015 122

Number of Products by Stage and Mechanism of Action, H1 2015 125

Number of Products by Stage and Route of Administration, H1 2015 127

Number of Products by Stage and Molecule Type, H1 2015 129

Hepatitis B Therapeutics-Recent Pipeline Updates, H1 2015 296

Hepatitis B-Dormant Projects, H1 2015 325

Hepatitis B-Dormant Projects (Contd..1), H1 2015 326

Hepatitis B-Dormant Projects (Contd..2), H1 2015 327

Hepatitis B-Dormant Projects (Contd..3), H1 2015 328

Hepatitis B-Dormant Projects (Contd..4), H1 2015 329

Hepatitis B-Dormant Projects (Contd..5), H1 2015 330

Hepatitis B-Dormant Projects (Contd..6), H1 2015 331

Hepatitis B-Dormant Projects (Contd..7), H1 2015 332

Hepatitis B-Dormant Projects (Contd..8), H1 2015 333

Hepatitis B-Discontinued Products, H1 2015 334

List of Figures

Number of Products under Development for Hepatitis B, H1 2015 23

Number of Products under Development for Hepatitis B-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 25

Number of Products under Investigation by Universities/Institutes, H1 2015 33

Comparative Analysis by Late Stage Development, H1 2015 35

Comparative Analysis by Clinical Stage Development, H1 2015 36

Comparative Analysis by Early Stage Products, H1 2015 37

Assessment by Monotherapy Products, H1 2015 119

Assessment by Combination Products, H1 2015 120

Number of Products by Top 10 Targets, H1 2015 121

Number of Products by Stage and Top 10 Targets, H1 2015 121

Number of Products by Top 10 Mechanism of Actions, H1 2015 124

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 124

Number of Products by Top 10 Routes of Administration, H1 2015 126

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 126

Number of Products by Top 10 Molecule Types, H1 2015 128

Number of Products by Stage and Top 10 Molecule Types, H1 2015 128

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abivax S.A.

AiCuris GmbH & Co. KG

Akshaya Bio Inc.

Alnylam Pharmaceuticals, Inc.

AlphaMab Co., Ltd

AltraVax Inc.

Amarna Therapeutics B.V.

Arrowhead Research Corporation

Assembly Biosciences, Inc.

Beijing Minhai Biotechnology Co., Ltd

Benitec Biopharma Limited

Big DNA Ltd.

BioDiem Ltd

Biogenomics Limited

Biological E. Limited

BioStar Pharmaceuticals, Inc.

Bolder Biotechnology, Inc.

Bukwang Pharm.Co., Ltd.

Celltrion, Inc.

Chimerix, Inc.

Chongqing Zhifei Biological Products Co., Ltd.

ChronTech Pharma AB

Cytos Biotechnology AG

Dynavax Technologies Corporation

Enyo Pharma S.A.S.

F. Hoffmann-La Roche Ltd.

GeneCure LLC

Genexine, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Green Cross Corporation

HEC Pharm Co., Ltd.

Humabs BioMed SA

Ildong Pharmaceutical Co., Ltd.

Immunotope, Inc.

Immunovaccine, Inc.

Inbiopro Solutions Pvt. Ltd.

Indian Immunologicals Limited

iQur Limited

ISA Pharmaceuticals B.V.

Isis Pharmaceuticals, Inc.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Johnson & Johnson

Leukocare AG

LG Life Sciences, Ltd.

Ligand Pharmaceuticals, Inc.

Mologen AG

Mucosis B.V.

MultiCell Technologies, Inc.

Novira Therapeutics, Inc.

Panacea Biotec Limited

Pfenex Inc.

PharmaEssentia Corporation

Redx Pharma Plc

REPLICor Inc.

Romark Laboratories, L.C.

Sanofi Pasteur SA

SEEK Group

Sinovac Biotech Ltd.

SK Chemicals Co., Ltd.

Spring Bank Pharmaceuticals, Inc.

TCM Biotech International Corp

Tekmira Pharmaceuticals Corp.

TetraLogic Pharmaceuticals

Theravectys S.A.

Transgene SA

Vaxine Pty Ltd

Viriom Ltd.

VLP Biotech, Inc.

WaterStone Pharmaceuticals, Inc.

Zydus Cadila Healthcare Limited

Hepatitis B Therapeutic Products under Development, Key Players in Hepatitis B Therapeutics, Hepatitis B Pipeline Overview, Hepatitis B Pipeline, Hepatitis B Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com